CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia.

Xiong-Yu Liao, Jian-Pei Fang, Dun-Hua Zhou, Kun-Yin Qiu

Hematological oncology 2022 Apr

filter terms:

To evaluate the outcome and prognostic significance of CEBPA mutations among pediatric acute myeloid leukemia (AML) from TARGET dataset. A total of 1803 pediatric patients who were diagnosed with AML were classified into two groups based on the CEBPA status by using a retrospective cohort study method from September 1996 to December 2016. The incidence of CEBPA mutations was 18%. CEBPA mutations were significantly associated with elder age (p < 0.001), higher WBC (p = 0.004), higher proportion of peripheral blood blast (p < 0.001), normal karyotype (p < 0.001), low risk (p < 0.001) and higher complete remission induction rates (p < 0.05). Overall, CEBPA mutations patients had a significantly better 5-year EFS (p < 0.001) and OS (p < 0.001) compared to CEBPA wild-type patients, and this favorable impact was maintained even in the presence of FLT3/ITD mutations. Stem cell transplantation had no significant impact on the survival of patients with coexistence of CEBPA and FLT3/ITD mutations. Multivariate analysis demonstrated that mutated CEBPA were an independent favorable indicators of better outcome in terms of EFS (p = 0.007) and OS (p = 0.039). Our study demonstrate mutated CEBPA have an excellent outcome in pediatric AML patients. Furthermore, pediatric AML patients with coexistence of CEBPA and FLT3/ITD mutation appear to have favorable prognoses and might not required stem cell transplantation. © 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.

Citation

Xiong-Yu Liao, Jian-Pei Fang, Dun-Hua Zhou, Kun-Yin Qiu. CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia. Hematological oncology. 2022 Apr;40(2):258-268